Central Nervous System Treatment Market Size [2022-2028] | is Anticipated to Reach USD 166.53 Billion, Exhibit a CAGR 0f 9.4%
07 janv. 2022 03h53 HE
|
Fortune Business Insights
Pune, India, Jan. 07, 2022 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is anticipated to reach USD 166.53 billion by 2028 and exhibit a CAGR 0f 9.4% during the...
VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference
16 nov. 2021 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of...
Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference
10 nov. 2021 16h15 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
14 oct. 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional Anxiety Disorders Phase 2A Study in Adjustment Disorder to Run in Parallel with Ongoing Phase 3...
Vyant Bio to Present at the H.C. Wainwright 23rd Annual Global Conference
09 sept. 2021 08h00 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
16 août 2021 08h00 HE
|
Praxis Precision Medicines, Inc.
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms
16 août 2021 07h55 HE
|
Praxis Precision Medicines, Inc.
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile ...
Vyant Bio Announces Investor Conference Call and Webcast for Second Quarter 2021
11 août 2021 09h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Global Central Nervous System Disorders Therapeutics Market to Surpass US$ 202.7 Million by 2028, Says Coherent Market Insights (CMI)
05 août 2021 09h15 HE
|
CMI
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global central nervous system disorders therapeutics market is estimated to be valued at US$ 131.3 million in...
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
13 juil. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...